Tipping the extracellular matrix balance during heart failure progression: Do we always go right?

Cardiology

Volumn 116, Issue 2, 2010, Pages 130-132

  Chiao, Ying Ann ^a   Jin, Yu Fang ^b   Lindsey, Merry L ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b The University of Texas at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; GELATINASE A; GELATINASE B; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE;

DISEASE COURSE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE DELETION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; METABOLISM;

DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77954209680     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315349     Document Type: Note

References (17)

1. Vanhoutte D, Heymans S: TIMPs and cardiac remodeling: 'embracing the MMP-inde-pendent-side of the family'. J Mol Cell Cardiol 2010;48:445-453.
2. Zamilpa R, Lindsey ML: Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol 2010;48:558-563.
3. Spinale FG: Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
4. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A: Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol 2003;285:H1229- 1235.
5. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClis-ter DM Jr, Su H, Gannon J, MacGillivray C, Lee RT, Sinusas AJ, Spinale FG: Matrix me-talloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol 2006; 290:H232-H239.
6. Creemers EEJM, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, Hauet AM, Escobar PG, Cleutjens JPM, Smits JFM, Dae-men MJAP, Zile MR, Spinale FG: Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol 2003; 284:H364-H371.
7. Matsumura S, Iwanaga S, Mochizuki S, Oka-moto H, Ogawa S, Okada Y: Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005; 115: 599-609.
8. Peterson JT: The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Car- diovasc Res 2006; 69: 677-687.
9. Yang D, Ma S, Tan Y, Chen Y, Li D, Tang B, Chen J, Su X, Li G, Zhang X, Yang Y: Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fi-bronectin expression in patients with congestive heart failure. Cardiology 2010;116:133-141
10. Lindsay MM, Maxwell P, Dunn FG: TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40:136-141.
11. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141:211-217.
12. Cavusoglu E, Ruwende C, Chopra V, Yana-madala S, Eng C, Clark LT, Pinsky DJ, Mar-mur JD: Tissue inhibitor of metalloprotein-ase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101.e1-1101.e8.
13. Frantz S, Stork S, Michels K, Eigenthaler M,Ertl G, Bauersachs J, Angermann CE: Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008;10: 388-395.
14. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL: Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol 2005; 288:H461-H468.
15. Morodomi T, Ogata Y, Sasaguri Y, Morima-tsu M, Nagase H: Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fi-brosarcoma cells. Biochem J 1992; 285:603611.
16. Trial J, Rossen RD, Rubio J, Knowlton AA: Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp Biol Med 2004; 229:538-545.
17. Austin BA, Liu B, Li Z, Nussenblatt RB: Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium. Invest Ophthalmol Vis Sci 2009;50:2896-2902.